Item 2.02 - Results of Operations and Financial Condition.

On January 9, 2023, Amicus Therapeutics, Inc. (the "Company") issued a press release announcing preliminary 2022 revenue and its 2023 strategic outlook, along with various business updates. A copy of the press release is attached hereto as Exhibit 99.1. As previously announced, the Company will also be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 9th, 2023. A copy of the presentation materials management will be using at the conference is also attached hereto as Exhibit 99.2. Both exhibits are incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits:



    Exhibit No.                            Description
        99.1       Press Release dated January 9, 2023

                   Presentation Materials - 41st Annual J.P. Morgan Healthcare
        99.2     Conference

                 Cover Page Interactive Data File (embedded within the Inline
        104      XBRL document)

© Edgar Online, source Glimpses